Clinical and PET/CT metabolic imaging characteristics across the evolving spectrum of visceral leishmaniasis and associated hemophagocytic lymphohistiocytosis - Takeaways - MDSpire

Clinical and PET/CT metabolic imaging characteristics across the evolving spectrum of visceral leishmaniasis and associated hemophagocytic lymphohistiocytosis

  • By

  • Chao Yang

  • Yan Wang

  • Ruixian Duan

  • Feiyan Wei

  • Xiu Sun

  • July 13, 2026

Share

  • 1

    The study involved 21 patients with visceral leishmaniasis, categorized into VL-only, VL-HLH, and a Grey Zone group.

  • 2

    The VL-HLH group showed significantly higher C-reactive protein levels and spleen thickness compared to the VL-only group.

  • 3

    PET/CT identified the spleen and bone marrow as primary metabolic targets, with splenic SUVmax correlating with D-dimer and ferritin.

  • 4

    A simple risk score based on C-reactive protein and spleen thickness effectively stratified patients by disease severity.

  • 5

    The study highlights the systemic inflammation-coagulation-tissue injury network in VL and the need for improved diagnostic tools.

Original Source(s)

Clinical and PET/CT metabolic imaging characteristics across the evolving spectrum of visceral leishmaniasis and associated hemophagocytic lymphohistiocytosis

  • by Chao Yang, Yan Wang, Ruixian Duan, Feiyan Wei, Xiu Sun

  • July 13, 2026

Related Content

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.

Effectiveness and tolerability of cephalexin and clavulanic acid fixed dose combination, amoxicillin and clavulanic acid fixed dose combination, and azithromycin in patients with pharyngitis in India: a real-world retrospective study from electronic medical records (PHARYSPOR)

A Controlled Comparison of Human and AI-Assisted Automated Revision of Delphi Statements on RNA-Based Medicines: Parallel, 2-Arm Study